Preskoči na sadržaj
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Sva polja
Naslov
Autor
Tema
Signatura
ISBN/ISSN
Oznaka
Pronađi
Napredno
Preliminary phase IISOCRATES s...
Citiraj ovo
Pošalji tekstualnu poruku
Pošalji ovo e-mailom
Ispiši
Izvezi zapis
Izvezi u RefWorks
Izvezi u EndNoteWeb
Izvezi u EndNote
Stalna poveznica
Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
Bibliografski detalji
Glavni autori:
Glynne-Jones, R
,
Sebag-Montefiore, D
,
McDonald, A
,
Falk, S
,
Maughan, T
Format:
Conference item
Izdano:
2004
Primjerci
Opis
Slični predmeti
Prikaz za djelatnike knjižnice
Opis
Sažetak:
Slični predmeti
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
od: Glynne-Jones, R, i dr.
Izdano: (2005)
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
od: Sebag-Montefiore, D, i dr.
Izdano: (2005)
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
od: Glynne-Jones, R, i dr.
Izdano: (2007)
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
od: Evans, T, i dr.
Izdano: (2006)
Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
od: Anchuan Li, i dr.
Izdano: (2022-07-01)